🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Neoadjuvant Chemotherapy for Colon Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials - European Journal of Cancer ejcancer.com/article/S0959-…

Advances and challenges in targeted therapies for HER2-amplified colorectal cancer - European Journal of Cancer ejcancer.com/article/S0959-…

A Phase III RCT Crossover Trial to Evaluate the Efficacy of Olanzapine in Combination with Fosaprepitant, Ondansetron, and Dexamethasone for the Prevention of CINV in Patients with Germ Cell Tumor Undergoing a 5-Day Cisplatin-based Chemotherapy ejcancer.com/article/S0959-…

Neoadjuvant IO in Muscle invasive bladder cancer; Encouraging pCr and 1 year RFS rates ESMO - Eur. Oncology

Combination of TAR 200 + cetrelimab is a viable option as NACT in platinum ineligible pts (MIBC)with encouraging path Crs; SUNRISE 4 trial ESMO - Eur. Oncology

🦠Is CMV seropositivity associated with efficacy and toxicity of IO❓ Nature Medicine ➡️Malign melanoma ❌No with combination anti-CTLA-4/anti-PD-1 ✅Improved OS with single-agent anti-PD-1 ❗️✅reduced cumulative incidence of grade 3+ irAE 👉doi.org/10.1038/s41591… OncoAlert

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: a pooled analysis of TRIBE and TRIBE2 studies - European Journal of Cancer ejcancer.com/article/S0959-…

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma European Urology europeanurology.com/article/S0302-…

In early-stage dMMR cancers, neoadjuvant PD-1 blockade achieved 92% 2-year recurrence-free survival — many patients avoided surgery. A new era in organ preservation! #AACR25 #CancerResearch ⁦OncoAlert⁩ ⁦OncoDaily⁩ ⁦LARVOL⁩ nejm.org/doi/full/10.10…

‼️Divergent histology in bladder cancer impacts outcomes and genomics. ‼️In 3052 RC patients, UCAH subtypes (plasmacytoid, micropapillary, sarcomatoid) showed worse survival. 🎯Genomic targets: ERBB2 (micropapillary), FGFR3 (nested/squamous), PTEN (sarcomatoid).

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC AACR #AACR25 #HNSCC #HeadandNeckCancer onclive.com/view/periopera…

Impressive preliminary efficacy & safety of Zoldonrasib (RMC-9805) in KRAS G12D NSCLC 🔹MOA: oral RAS(ON) covalent, mutant-selective, G12D inhibitor 🔹 In 18 evaluable patients: ORR 61%, DCR 89% 🔹≥50% ctDNA clearance seen in majority of patients with detectable ctDNA at

MUC1-C is a potential target for all HR+ Her2 neg drug resistant tumors. Future ADC target loading!! 😉 Dr Akhil Santhosh Sara Tolaney Hope Rugo Matteo Lambertini, MD PhD Josh Thomas Georgy ONCO BRUNO #bcsm doi.org/10.1038/s41523…

ctDNA is prognostic in advanced GE jn adenocarcinoma. Results from PRODIGE 59 - DURIGAST Pashtoon Kasi MD, MS Dr Amol Akhade Dr Akhil Santhosh doi.org/10.1038/s43856…

Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population 📌PTVs in BRCA2 exon 11 are associated with lower BC risk, older age at diagnosis, and higher risk of ER-negative disease compared to other exons 💥Variant location may inform

Presented at #AACR25: Among patients with tumors harboring tyrosine kinase domain mutations who received zongertinib (a selective inhibitor of the HER2 tyrosine kinase), 71% had a response, and median progression-free survival was 12.4 months. Full study results:

Beamion LUNG 1 - Zongertinib in previously treated Her2 mutated NSCLC. Phase 1 data, 71% ORR, DoR 14.1m, mPFS 12.4m. Good safety profile. Promising data. DOI: 10.1056/NEJMoa2503704 Dr Amol Akhade Dr Akhil Santhosh Narjust Florez, MD, FASCO OncoAlert

Dr. Zhu presents AENEAS2 at #AACR25 Aumolertinib with or without chemotherapy as 1L tx for EGFR NSCLC Similar to FLAURA2 combination of TKI + chemo confirms improvement in PFS, 29 mo with combination vs. 19 mo in TKI only. OS data immature. #LCSM #LungCancer EGFR Resisters